Reporting onsite from AACR 2022 in New Orleans, Benoit Rousseau reviews the results from a study looking at the occurrence of POLE defects to predict the activity of nivolumab in solid tumours, and to specify the range of TMB application as a biomarker for immune checkpoint blockade. He further reviews the CheckMate 848 results comparing nivo+ipi vs nivo alone in metastatic solid tumours with high TMB, supporting the predictive value of TMB rather from tumour rather than from blood samples.
Abstracts:
- CT021 - PD-1 blockade in solid tumors with defects in polymerase epsilon - Benoît Rousseau, et al.
- CT022 - CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden - Michael Schenker, et al.